Non-viral gene therapies emerge as key players amid viral safety bottlenecks
Non-viral gene therapies may ease some safety, pricing and manufacturing challenges linked to viral vectors, but experts say both approaches will still have a place.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
